^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Nivolumab and pembrolizumab ± ibrutinib are included as options with a category 2B recommendation for patients unable to receive chemoimmunotherapy, patients with del (17p) or TP53 mutation, or those with chemoimmunotherapy-refractory disease.
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Excerpt:
...TP53 mutations, SF3B1 mutations, or NOTCH1 mutation....
Trial ID: